A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proteinuria
Timeframe: Measured on 24 hour urine collection on the last day in each treatment period (each treatment period is 4 weeks)
GFR
Timeframe: Measured on the last day in each treatment period (each treatment period is 4 weeks)